Digesting drug pricing, plus access in ALS

Build Back Better’s drug pricing provisions are likely to change investment decisions; it has a long road ahead

Build Back Better’s drug pricing provisions are likely to change investment decisions and have unintended consequences. On the latest BioCentury This Week podcast, BioCentury’s editors examine the potential impact of the complex piece of legislation and what needs to happen before it lands on President Biden’s desk.

The editors also discuss access to therapies for amyotrophic lateral sclerosis, including via FDA approval and through broader access to products in clinical testing.

This week’s Emerging Company Spotlight homes in on Parthenon Therapeutics Inc., which is creating a pipeline of cancer therapies designed to break down the physical barriers in the tumor microenvironment that shield tumors from immune cells, and OncoHost Ltd., an Israeli company developing a platform to predict the host response to a cancer therapy, which could enable personalized treatment strategies, improve outcomes and reduce side effects.